Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 7;8(6):ofab110.
doi: 10.1093/ofid/ofab110. eCollection 2021 Jun.

Considerations for Assessment and Deployment of Rapid Antigen Tests for Diagnosis of Coronavirus Disease 2019

Nira R Pollock  1 , Francesca Lee  2 , Christine C Ginocchio  3 , Joseph D Yao  4 , Romney M Humphries  5
Affiliations

Considerations for Assessment and Deployment of Rapid Antigen Tests for Diagnosis of Coronavirus Disease 2019

Nira R Pollock et al. Open Forum Infect Dis. .

Abstract

Diagnostic testing is a critical tool to mitigate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, but molecular testing capacity remains limited. Rapid diagnostic tests (RDTs) that detect SARS-CoV-2 protein antigens (Ag) offer the potential to substantially expand testing capacity and to allow frequent, large-scale, population screening. Testing is simple, rapid (results generally available within 15 minutes), and applicable for diagnosis at point of care. However, implementation of Ag RDTs requires a detailed understanding of test performance and operational characteristics in each testing scenario and population being evaluated. Successful implementation of Ag RDTs on a large scale should combine testing with technical oversight and with clinical and public health infrastructure, and will require production at levels much higher than presently possible. In this commentary, we provide detailed considerations for Ag RDT assessment and use cases to encourage and enable broader manufacturing and deployment.

Keywords: COVID; SARS-CoV-2; antigen; diagnostic; point-of-care.

PubMed Disclaimer

References

    1. US Food and Drug Administration. Individual EUAs for antigen diagnostic tests for SARS-CoV-2. Available at: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-em.... Accessed 22 February 2021.
    1. Centers for Disease Control and Prevention. Interim guidance for antigen testing for SARS-CoV-2. Available at: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-gu.... Accessed 13 February 2021.
    1. Rubin R. The challenges of expanding rapid tests to curb COVID-19. JAMA 2020. doi: 10.1001/jama.2020.21106. - DOI - PubMed
    1. Nevada Department of Health and Human Services. Available at: http://dpbh.nv.gov/uploadedFiles/dpbhnvgov/content/Resources/Directive%2.... Accessed 13 February 2021.
    1. Pray IW, Ford L, Cole D, et al. . Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses - Wisconsin, September-October 2020. MMWR Morb Mortal Wkly Rep 2021; 69:1642–7. - PMC - PubMed